

Department of Planning and Budget

2017 Fiscal Impact Statement

1. Bill Number: HB 1799H1

House of Origin	<input type="checkbox"/> Introduced	<input checked="" type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
Second House	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input type="checkbox"/> Enrolled

2. Patron: O'Bannon

3. Committee: Courts of Justice

4. Title: Board of Pharmacy to deschedule or reschedule cannabidiol upon publication of an interim final rule.

5. Summary: The bill provides that no person shall be prosecuted for prescribing, administering, dispensing, or possessing pursuant to a valid prescription issued by a prescriber any substance that has been approved as a prescription drug by the U.S. Food and Drug. Such immunity from prosecution for a particular substance shall remain in effect until the earlier of nine months as calculated from the latter of the date of the publication in the Federal Register of the interim final rule scheduling such substance or the final rule scheduling such substance, provided that a final rule is issued within nine months of the interim final rule. The Board shall post notice of the hearing on the Virginia Regulatory Town Hall and shall send notice of the hearing to any persons requesting to be notified of a regulatory action. The Board shall include a list of all substances it intends to schedule by regulation in such notice.

6. Budget Amendment Necessary: No.

7. No Fiscal Impact.

8. Fiscal Implications: This bill would not have a fiscal impact on the Commonwealth. The Board can absorb any additional workload associated with the provisions of the bill.

9. Specific Agency or Political Subdivisions Affected: None.

10. Technical Amendment Necessary: No.

11. Other Comments: SB 1403, introduced by Senator Dunnavant, is a companion bill.